THE POTENTIAL OF INTERLEUKIN 17 AS A PROGNOSTIC BIOMARKER AND A TARGET OF THERAPEUTIC MODALITIES IN ATOPIC DERMATITIS

  • Kardiana Purnama Dewi School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia
Keywords: Atopic Dermatitis, Correlation, Interleukin-17, Pro-inflammatory mediator, SCORAD index

Abstract

Background. Atopic dermatitis (AD) is one of the most common chronic relapsing inflammatory skin disease. AD causes negative impacts on social and economic, especially on the patients’ and their families’ quality of life. The immune dysregulation in AD resulting in disruption of keratinocyte barrier and inflammation AD recently was associated with the response of TH17, which produce IL-17. This study aims to investigate the correlation of IL-17 with severity of AD.

Methods. This retrospective cohort study was conducted in dermatovenerology outpatient department. Consecutive sampling was done during the period of the study on patients aged more than 14 years old diagnosed with AD. Demographic data, Scoring for AD (SCORAD) index, stress score, onset and duration of disease, and three mililitres of whole blood in vacutainer were obtained. IL-17 serum level analysis was measured on the blood by ELISA technique according to manufacturer’s protocol. P-value smaller than 0.05 was appraised as statistically significant.

Results. There were significantly higher IL-17 serum level in AD patients compared with control patients. There were higher IL-17 serum level in moderate-severe compared to mild AD patients. There were also significantly longer in the duration of the disease and higher SCORAD index in moderate-severe compared to mild AD patients. There was very strong positive correlation between IL-17 serum level and SCORAD index.

Conclusions. The findings of this study emphasize the potency of IL-17 as prognostic biomarkers and also as the potential target of therapeutic modalities.

Downloads

Download data is not yet available.

References

Chovatiya R, Silverberg JI. Pathophysiology of atopic dermatitis and psoriasis: implications for management in children. Children (Basel). 2019;6:108.
2. Sugaya M. The role of Th17-related cytokines in atopic dermatitis. Int J Mol Sci. 2020;21:1314.
3. Xu X, van Galen LS, Koh MJA, Bajpai R, Thng S, Yew YW, et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: a cross-sectional study. Sci Rep. 2019;9:15990.
4. Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013;70:3–11.
5. Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract. 2014;2:371–9; quiz 380–1.
6. Kabashima-Kubo R, Nakamura M, Sakabe J, Sugita K, Hino R, Mori T, et al. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. J Dermatol Sci. 2012;67:37–43.
7. Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with Iinterleukin-17. PLoS One. 2016;11:e0161759.
8. Cheung PFY, Wong CK, Lam CWK. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol. 2008;180:5625–35.
9. Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor S, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21:104–10.
10. Honari G. Clinical Scoring of Atopic Dermatitis. In: Humbert P, Fanian F, Maibach HI, Agache P, editors. Agache’s Measuring the Skin: Non-invasive Investigations, Physiology, Normal Constants. Cham: Springer International Publishing; 2017. p. 1391–9.
11. Monin L, Gaffen SL. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 2018;10:a028522.
12. Mao Y, Yang C, Tang L, Liu G, Cheng L, Chen M. Increased expression of T helper 17 cells and interleukin-17 in atopic dermatitis: a systematic review and meta-analysis. Ann Palliat Med. 2021;10:12801–9.
13. Heo WI, Lee KE, Hong JY, Kim MN, Oh MS, Kim YS, et al. The role of interleukin-17 in mouse models of atopic dermatitis and contact dermatitis. Clin Exp Dermatol. 2015;40:665–71.
14. Tan Q, Yang H, Liu E, Wang H. Establishing a role for interleukin-17 in atopic dermatitis-related skin inflammation. J Cutan Med Surg. 2017;21:308–15.
15. Batista D i. s., Perez L, Orfali R l., Zaniboni M c., Samorano L p., Pereira N v., et al. Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis. J Eur Acad Dermatol Venereol. 2015;29:1091–5.
16. Leonardi S, Cuppari C, Manti S, Filippelli M, Parisi GF, Borgia F, et al. Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis syndrome (AEDS): Association with clinical severity and phenotype. Allergy Asthma Proc. 2015;36:74–81.
Published
2022-04-30
How to Cite
1.
Dewi K. THE POTENTIAL OF INTERLEUKIN 17 AS A PROGNOSTIC BIOMARKER AND A TARGET OF THERAPEUTIC MODALITIES IN ATOPIC DERMATITIS [Internet]. Damianus Journal of Medicine [Internet]. 30Apr.2022 [cited 3Jul.2022];21(1):72-7. Available from: https://ejournal.atmajaya.ac.id/index.php/damianus/article/view/3304
Abstract viewed = 12 times
PDF downloaded = 17 times